Use access key #2 to skip to page content.

Closing VRUS (Pharmasset) underperform

Recs

1

January 08, 2008 – Comments (1)

Another prediction came true, to a degree even beyond my expectations. Unfortunately work is busy today and I missed the top, losing about 30 CAPS points in each direction as I reversed to a thumbs down. Hepatitis C is clearly proving itself as an agent of change. I expect the next major change for Pharmasset will be downward, however, as R7128 is either shown to cause hepatotoxicity or is simply not as effective as hoped for in later stage trials. See Vertex or Idenix for similar stories.

1 Comments – Post Your Own

#1) On February 15, 2008 at 10:52 AM, zzlangerhans (99.78) wrote:

The title should obviously read "Closing VRUS (Pharmasset) outperform".

Report this comment

Featured Broker Partners


Advertisement